Pomalidomide-amido-C1-Br

Cat. No.:	HY-130617
CAS No.:	2351106-38-0
Molecular Formula:	$C_{15}H_{12}BrN_3O_5$
Molecular Weight:	394.18
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



BIOLOGICAL ACTIVITY

Description	Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758). PROTAC B-Raf degrader 1 has anti-cancer activity[1].
IC_{50} & Target	Cereblon
In Vitro	Pomalidomide-amido-C1-Br (Compound 6) can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (Compound 2). PROTAC B-Raf degrader 1 can effectively kill cancer cells via inducing cells apoptosis. As a B-Raf degrader, PROTAC B-Raf degrader 1 can accelerate the degradation of B-Raf by recruiting ubiquitin-proteasome system, and further affects the expression of Mcl-1, a downstream protein of B-Raf[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Chen H, et al. Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation. Bioorg Chem. 2019 Jun;87:191-199.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA